drugset / Trial / NCT03297606
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Phase 2
Recruiting
720 enrolled
Canadian Cancer Trials Group
AstraZeneca · collabBristol-Myers Squibb · collabHoffmann-La Roche · collabPfizer · collabSeagen Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.
Timeline
- Start
- 2018-03-23
- Primary completion
- 2026-12-31
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | Oral |
| Subject | Bosutinib | Small molecule | 500 mg | Oral |
| Subject | Cobimetinib | Small molecule | 60 mg | Oral |
| Subject | Crizotinib | Small molecule | 250 mg | Oral |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | Palbociclib | Small molecule | 125 mg | Oral |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | Intravenous |
| Subject | Sunitinib | Small molecule | 50 mg | Oral |
| Subject | Temsirolimus | Small molecule | 25 mg | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |
| Subject | Tucatinib | Small molecule | 300 mg | Oral |
| Subject | Vemurafenib | Small molecule | 960 mg | Oral |
| Subject | Vismodegib | Small molecule | 150 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |